SG11202107966TA - Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors - Google Patents
Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumorsInfo
- Publication number
- SG11202107966TA SG11202107966TA SG11202107966TA SG11202107966TA SG11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA SG 11202107966T A SG11202107966T A SG 11202107966TA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- fusion proteins
- extracellular domain
- negative tumors
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962809319P | 2019-02-22 | 2019-02-22 | |
US201962815249P | 2019-03-07 | 2019-03-07 | |
PCT/US2020/019135 WO2020172482A2 (en) | 2019-02-22 | 2020-02-21 | Cd80 extracellular domain fc fusion proteins for treating pd-l1 negative tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107966TA true SG11202107966TA (en) | 2021-09-29 |
Family
ID=70057229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107966TA SG11202107966TA (en) | 2019-02-22 | 2020-02-21 | Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220031806A1 (en) |
EP (1) | EP3927365A2 (en) |
JP (1) | JP2022521299A (en) |
KR (1) | KR20210130706A (en) |
AU (1) | AU2020224137A1 (en) |
CA (1) | CA3130752A1 (en) |
MX (1) | MX2021010061A (en) |
SG (1) | SG11202107966TA (en) |
TW (1) | TW202045544A (en) |
WO (1) | WO2020172482A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10273281B2 (en) | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
KR20190139216A (en) | 2017-04-28 | 2019-12-17 | 파이브 프라임 테라퓨틱스, 인크. | Therapeutic Methods Using CD80 Extracellular Domain Polypeptides |
WO2021092084A1 (en) * | 2019-11-04 | 2021-05-14 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain fc fusion protein dosing regimens |
CN112326961B (en) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | Analysis method and storage device for proportion of PD-L1 positive tumor cells in non-small cell lung cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1638941E (en) | 2003-05-22 | 2010-08-24 | Abbott Lab | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
DK3309174T3 (en) * | 2014-07-11 | 2022-06-07 | Ventana Med Syst Inc | ANTI-PD-L1 antibodies and diagnostic uses thereof |
US10273281B2 (en) * | 2015-11-02 | 2019-04-30 | Five Prime Therapeutics, Inc. | CD80 extracellular domain polypeptides and their use in cancer treatment |
-
2020
- 2020-02-21 WO PCT/US2020/019135 patent/WO2020172482A2/en unknown
- 2020-02-21 CA CA3130752A patent/CA3130752A1/en active Pending
- 2020-02-21 EP EP20715521.9A patent/EP3927365A2/en active Pending
- 2020-02-21 AU AU2020224137A patent/AU2020224137A1/en active Pending
- 2020-02-21 MX MX2021010061A patent/MX2021010061A/en unknown
- 2020-02-21 TW TW109105614A patent/TW202045544A/en unknown
- 2020-02-21 US US17/432,640 patent/US20220031806A1/en active Pending
- 2020-02-21 KR KR1020217023055A patent/KR20210130706A/en unknown
- 2020-02-21 JP JP2021549275A patent/JP2022521299A/en active Pending
- 2020-02-21 SG SG11202107966TA patent/SG11202107966TA/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210130706A (en) | 2021-11-01 |
MX2021010061A (en) | 2021-12-10 |
WO2020172482A3 (en) | 2020-10-01 |
JP2022521299A (en) | 2022-04-06 |
WO2020172482A2 (en) | 2020-08-27 |
EP3927365A2 (en) | 2021-12-29 |
TW202045544A (en) | 2020-12-16 |
AU2020224137A1 (en) | 2021-10-14 |
US20220031806A1 (en) | 2022-02-03 |
CA3130752A1 (en) | 2020-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202107966TA (en) | Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors | |
IL292551B1 (en) | Compositions and methods for t-cell receptors reprogramming using fusion proteins | |
IL285702A (en) | Heterocyclic amides useful as protein modulators | |
ZA202100125B (en) | Novel fusion protein specific for cd137 and pd-l1 | |
IL262094A (en) | Heterocyclic amides useful as protein modulators | |
EP3223730A4 (en) | Method and apparatus for joint fusion | |
PT3532036T (en) | Process for isolating and lyophilizing extracellular vesicles | |
EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
EP3491286A4 (en) | Artificial light compensation system and process | |
EP3610192A4 (en) | Hybrid lens for controlled backlight distribution | |
EP3225690A4 (en) | Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use thereof | |
EP3527980A4 (en) | Method for recovering extracellular vesicles | |
GB2587988B (en) | Method for enhancing the suppressive properties of Treg cells | |
EP3461506A4 (en) | Material for intraocular lenses | |
EP3660143A4 (en) | Method for isolating extracellular vesicle using hydrophobic interaction | |
IL281003A (en) | Cd80 extracellular domain fc fusion protein dosing regimens | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
SG11202000775SA (en) | Fusion tags for recombinant protein expression | |
EP3869177A4 (en) | Method for recovering extracellular vesicles | |
GB201915855D0 (en) | An extracellular vesicle | |
EP3619564A4 (en) | Light system for supplying light | |
EP3139955A4 (en) | Fusion proteins for treating cancer and related methods | |
EP3730603A4 (en) | Method for stabilizing extracellular vesicles | |
IL266183B (en) | Fused azaheterocyclic compounds and their use as ampa receptor modulators | |
EP3673650A4 (en) | Vision system for laboratory workflows |